Short Interest in Jaguar Health, Inc. (NASDAQ:JAGX) Increases By 29.6%

Jaguar Health, Inc. (NASDAQ:JAGX) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 430,700 shares, an increase of 29.6% from the October 31st total of 332,300 shares. Based on an average daily volume of 266,600 shares, the days-to-cover ratio is presently 1.6 days. Currently, 5.6% of the company’s shares are sold short.

Jaguar Health Stock Down 2.9 %

NASDAQ:JAGX traded down $0.03 during mid-day trading on Monday, hitting $1.01. The company had a trading volume of 245,354 shares, compared to its average volume of 717,602. The company has a current ratio of 1.84, a quick ratio of 1.36 and a debt-to-equity ratio of 1.65. Jaguar Health has a 1 year low of $0.90 and a 1 year high of $24.30. The business has a fifty day simple moving average of $1.12 and a 200-day simple moving average of $2.37.

Institutional Trading of Jaguar Health

A hedge fund recently bought a new stake in Jaguar Health stock. Perritt Capital Management Inc acquired a new position in Jaguar Health, Inc. (NASDAQ:JAGX) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned approximately 0.51% of Jaguar Health at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.04% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Jaguar Health from a “sell” rating to a “hold” rating in a research note on Friday, September 13th.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.